EUVIMEDEUVIMED entdecken
Crossref

Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial

Sicherheit telemedizinischer Nachsorgevisiten bei Kindern mit Krebs unter intensiver Chemotherapie: Ergebnisse der randomisierten KULT-SH-Studie

Denis M Schewe iD, Annika Rademacher iD, Patricia Kattner, Verena Winkeler iD, Christine Heinen, Jana Dördelmann iD, Christiane Heydrich-Karsten, Jakob Thiel, Martin Schrappe iD, Britta Exner iD, Fabian-Simon Frielitz

JCO Oncology Practice · 27.05.2026

DOI: 10.1200/op-25-01303 ↗

Auf einen Blick

In einer randomisierten Crossover-Studie waren telemedizinische und persönliche Nachsorgevisiten bei Kindern mit Krebs unter intensiver Chemotherapie mit ähnlichen Raten schwerer unerwünschter Ereignisse verbunden.

Fragestellung

Ist die telemedizinische Nachsorge bei Kindern mit malignen Erkrankungen unter intensiver Chemotherapie hinsichtlich schwerer unerwünschter Ereignisse sicher?

Methode

Phase-III-randomisierte Crossover-Studie an 2 Universitätskliniken in Norddeutschland; 55 Patient:innen im Alter von 1-25 Jahren; TV oder IPV für 3 Monate, dann Crossover.

Ergebnisse

55 Patient:innen. Mittlere kumulative CTCAE-Scores ähnlich: TV 4,09 ± 4,26 vs. IPV 4,00 ± 3,95; mittlere Differenz –0,05 (95 %-KI –1,51 bis 1,41; P=.949). 337 Krankenhausbesuche vermieden, 42.288 km Reise.

Schlussfolgerung der Autor:innen

Telemedizinische Nachsorgevisiten sind während intensiver Chemotherapie eine praktikable Alternative zur persönlichen ambulanten Versorgung, mit geringerem Reiseaufwand ohne Hinweis auf mehr unerwünschte Ereignisse.

Kernaussagen

  • Ähnliche CTCAE-Scores unter Telemedizin und persönlicher Nachsorge
  • 337 Krankenhausbesuche und 42.288 km Reise vermieden
  • Kein Hinweis auf mehr schwere unerwünschte Ereignisse

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 27.05.2026. Verfasst von Denis M Schewe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology/Oncology, University Hospital Dresden, Technical University Dresden, National Center for Tumor Diseases (NCT) Partner Site Dresd…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Centralization of pediatric oncology care has increased the need for telemedicine. Evidence on its safety in highly vulnerable patients such as children undergoing intensive chemotherapy remains limited. METHODS KULT-SH was a phase III randomized crossover trial at two university hospitals in Northern Germany. Patients age 1-25 years with malignant diseases received either telemedicine follow-up visits (TV) or in-person outpatient follow-up visits (IPV) for 3 months, followed by crossover to the alternate mode. TV included video visits and electronic transmission of vital signs. The primary end point, evaluated in the intention-to-treat population, was the cumulative number of severe adverse events (Common Terminology Criteria for Adverse Events grade ≥3). For analysis, data from both crossover sequences were combined for the TV and IPV phases. RESULTS Between June 2021 and May 2024, 55 patients (mean age 8.7 ± 6.0 years; 58% male) were randomly assigned. Overall, 18% of outpatient visits were delivered via telemedicine. 337 hospital visits were avoided, corresponding to 42,288 km of travel. Mean cumulative Common Terminology Criteria for Adverse Events scores were similar between phases (TV 4.09 ± 4.26 v IPV 4.00 ± 3.95; mean difference –0.05, 95% CI, –1.51 to 1.41; P = .949), indicating comparable rates of adverse events between TV and IPV. The most frequent grade 3-4 events were febrile neutropenia and gastrointestinal complications; no deaths occurred. Symptom-to-antibiotic time did not differ significantly between groups. CONCLUSION Telemedicine follow-up visits represent a feasible alternative to in-person outpatient care during intensive chemotherapy, reducing travel burden without evidence of increased adverse events.

Autor:innen und Institutionen

  • Pediatric Hematology/Oncology, University Hospital Dresden, Technical University Dresden, National Center for Tumor Diseases (NCT) Partner Site Dresden, Dresden, Germany.
  • Department of Pediatrics I, Pediatric Hematology and Oncology, Christian-Albrechts University and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Telemedicine, Digitalization, and Economics in Medicine, Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

ORCID-Profile: Denis M Schewe, Annika Rademacher, Verena Winkeler, Jana Dördelmann, Martin Schrappe, Britta Exner

Zitieren

APA

Schewe, D. M., Rademacher, A., Kattner, P., Winkeler, V., Heinen, C., Dördelmann, J., Heydrich-Karsten, C., Thiel, J., Schrappe, M., Exner, B., & Frielitz, F. S. (2026). Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial. JCO Oncology Practice. https://doi.org/10.1200/op-25-01303

Vancouver

Schewe DM, Rademacher A, Kattner P, Winkeler V, Heinen C, Dördelmann J, et al. Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial. JCO Oncology Practice. 2026. doi:10.1200/op-25-01303

BibTeX
@article{Schewe2026,
  author = {Schewe, Denis M and Rademacher, Annika and Kattner, Patricia and Winkeler, Verena and Heinen, Christine and Dördelmann, Jana and Heydrich-Karsten, Christiane and Thiel, Jakob and Schrappe, Martin and Exner, Britta and Frielitz, Fabian-Simon},
  title = {Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-01303}
}
Kostenlos starten →